Bli medlem
Bli medlem

Du är här

2016-03-15

Enzymatica AB: NOTICE OF EXTRAORDINARY SHAREHOLDERS MEETING IN ENZYMATICA AB (PUBL)

The English text is an unofficial translation. In case of any discrepancies
between the Swedish text and the English translation, the Swedish text shall
prevail.

Press release
Lund on 15 March 2016

The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the "Company")
are hereby invited to attend the extraordinary shareholders' meeting to be
held on Thursday 14 April 2016 at 1.00 p.m. at Elite Hotel Ideon,
Scheelevägen 27 in Lund.

Right to participate and notice

Only shareholders that are recorded in their own name in the Company's share
ledger kept by Euroclear Sweden AB (The Swedish Central Securities Depository
Euroclear Sweden AB) as of 8 April 2016, and also have given notice on 8
April 2016 to the Company of their intent to participate, preferably no later
than 4.00 p.m., have the right to participate in the shareholders' meeting. A
shareholder may be accompanied by not more than two advisors, provided that
the number of such advisors has been notified to the Company no later than
the aforementioned time. Proxies need not notify the number of advisors in
advance.

Notice may be given in writing to Enzymatica AB (publ), att: EGM, Ideon
Science Park, 223 70 Lund or by e-mail
tocarl-johan.wachtmeister@enzymatica.com. The notice should specify the
shareholder's name, personal identity or Company registration number,
address, work-hour telephone number and shareholding, and names of any
advisors.

Trustee-registered shares

In order to be entitled to participate in the meeting, shareholders whose
shares are trustee-registered must temporarily register their shares in their
own names. Such registration should be requested from the trustee, and must
be executed with Euroclear Sweden AB on 8 April 2016. Shareholders that wish
to execute such registration must, well in advance before the said date,
notify its trustee thereof.

Proxies

If a shareholder intends to participate by proxy, the proxy must bring a
written and dated proxy signed by the shareholder in original to the meeting.
The proxy may not be older than five years. Proxy forms can be downloaded
from the Company's website, www.enzymatica.com. If the proxy is issued by a
legal entity, the proxy must also bring current registration certificate (Sw.
registreringsbevis) of the legal entity or similar document of authorisation
for the legal entity.

In order to facilitate registration, proxies and documents on authorisation
should be the Company to hand at the above-mentioned address well in advance
before the meeting, and at the latest on 8 April 2016.

Proposed agenda

1. Opening of the meeting
2. Election of chairman of the meeting
3. Preparation and approval of the register of voters
4. Approval of the agenda
5. Election of one or two persons to confirm the minutes
6. Determination as to whether the meeting has been duly convened
7. Resolution regarding amendment to the articles of association
8. Approval of the board of directors' resolution on a rights issue with
pre-emptive right for the shareholders
9. Resolution regarding authorisation of the board of directors to issue
shares
10. Closing of the meeting

Resolution proposals

Item 7: Resolution regarding amendment to the articles of association

The board of directors proposes, in order to enable the proposed new issues of
shares as set-forth in items 8-9 below, and subject to these, that the
articles of association are amended as follows:

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
| Current wording Proposed wording |
| § 4 The share capital shall be no less than SEK 500,000 and no more than SEK The share capital shall be no less than SEK |
| 2,000,000. |
| 1,500,000 and no more than SEK 6,000,000. |
| § 5 The number of shares in the Company shall not be lower than 12,500,000 and not The number of shares in the Company shall not be lower than 37,500,000 and not |
| higher than 50,000,000. higher than 150,000,000. |
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Item 8: Approval of the board of directors' resolution on a rights issue with
pre-emptive right for the shareholders

The board of directors proposes that the meeting approves the board of
directors' resolution on a rights issue on the following terms and
conditions.

* The Company's share capital shall be increased with a maximum amount of SEK
1,100,817.12 on a rights issue of a maximum of 27,520,428 shares with a
quotient value of SEK 0.04 per share.
* The Company's shareholders shall have pre-emptive right to subscribe for
new shares in proportion to the shares previously owned.
* Each previously owned share confers the right to one (1) subscription
right. Five (5) subscription rights entitles subscription for three (3) new
shares.
* The subscription price to be paid shall be SEK 2.18 for each new share.
* If not all shares are subscribed for by exercise of subscription rights in
accordance with the shareholders preferential rights mentioned above, the
board of directors shall resolve on allotment up to the maximum amount of
the share issue. In such case, priority will be givenfirstlyto those who
have also subscribed for shares by exercise of subscription rights, on the
occasion of oversubscription, pro rata in relation to their subscription
for shares by exercise of subscription rights and, to the extent not
possible, by drawing of lots.Secondly, allotment of shares subscribed for
without subscription rights shall be made to others who have subscribed for
shares without subscription rights, if full allotment is not possible, pro
rata in relation to their subscription for shares and, to the extent not
possible, by drawing of lots.Thirdly, allotment of shares shall be made to
those who have provided guarantees for the subscription of shares, pro rata
in relation to the guarantee provided.
* The record date for entitlement to participate in the rights issue with
pre-emptive right shall be 19 April 2016.
* Subscription for new shares shall be made during the time period as from 21
April 2016 - 6 May 2016. Subscription by exercise of subscription rights
shall be made by simultaneous cash payment. Subscription for new shares
without subscription rights shall be made on a separate subscription list.
Payment for new shares subscribed for without subscription rights shall be
made in cash no later than the third bank day from dispatch of the contract
note setting forth the allotment of shares to the subscriber. The board of
directors shall be entitled to extend the period for subscription and
payment.

Item 9: Resolution regarding authorisation of the board of directors to issue
new shares

The board of directors proposes that the meeting authorises the board of
directors until the next annual shareholders' meeting to, on one or more
occasions, resolve to increase the Company's share capital by issue of no
more than 17,500,000 new shares. However, such issues may not cause the share
capital in the Company to exceed the Company's highest allowed share capital
according to the articles of association. The board of directors may deviate
from the shareholders' preferential rights. The reason for the board of
directors' authorisation to deviate from the shareholders' preferential
rights is to enable the company's possibilities to raise new capital and to
take advantage of future opportunities to attract new long-term owners of
strategic importance to the company, as well as to finance the Company's
growth strategy. The authorization also includes the right to decide on
payment for the issued shares in kind, set-off or other conditions as
referred in Chap. 13 Sec. 5 item 6 of the Swedish Companies Act (Sw.
Aktiebolagslagen (2005:551)). At a deviation from the shareholders'
preferential rights, the issue rate shall be determined in accordance with
market conditions.

Particular majority requirements

For a valid resolution on the proposals pursuant to items 7 and 9, the
proposals have to be supported by shareholders representing at least
two-thirds of the votes cast as well as shares represented at the meeting.

Total number of shares and votes

The total number of shares and votes in the Company amounts as per the date of
this notice to 24,961,438. The company holds no shares. Following the
completion of the Company's acquisition of shares in Zymetech ehf., the total
number of shares and votes is estimated to increase by 20,905,942 before the
date of the meeting.

The shareholders are reminded of their right to request information from the
board of directors and the CEO at the meeting in accordance with Chap. 7 Sec.
32 of the Swedish Companies Act (Sw. Aktiebolagslagen (2005:551)).

Meeting documents

The board of directors' complete proposal for a resolution pursuant to items
7-9 and connected documents pursuant to Chap. 13 Sec. 6 of the Swedish
Companies Act (Sw. Aktiebolagslagen (2005:551)) are available for the
shareholders at the Company's website and at the Company at its above
mentioned address at the latest from 17 March 2016 and will free of charge be
sent to the shareholders upon their request to the Company, provided that
such share-holders state their current address.

Lund in March 2016
The board of directors

For further information, contact:
Fredrik Lindberg, CEO Enzymatica AB

Phone: 0708-86 53 70 | E-mail:fredrik.lindberg@enzymatica.com

About Enzymatica AB

Enzymatica is a life science company and its business concept is to offer
effective help against some of our most common diseases where viruses or
bacteria play a decisive role. In a short amount of time, the company has
developed ColdZyme® , a unique mount spray for colds, and launched the
product on six markets and established itself as the top selling product for
colds (calculated in SEK) in Swedish pharmacies. The development work
includes medical devices relating to upper respiratory tract infections and
oral health, as well as veterinary products. The company is headquartered in
Lund, Sweden, and is listed on Nasdaq First North. For more information,
please visit:www.enzymatica.se.

Press Release (PDF)
http://hugin.info/160850/R/1994302/734376.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire

HUG#1994302

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.